Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Receives $39.33 Consensus Price Target from Analysts

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have earned an average rating of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $39.3333.

A number of equities research analysts have recently issued reports on the stock. B. Riley Financial upped their price objective on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research note on Friday, March 20th. Wall Street Zen upgraded Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st. HC Wainwright boosted their price target on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Craig Hallum increased their price objective on Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Thursday, January 22nd.

Eton Pharmaceuticals Price Performance

Eton Pharmaceuticals stock opened at $24.99 on Thursday. Eton Pharmaceuticals has a 12-month low of $11.09 and a 12-month high of $25.99. The company has a quick ratio of 1.17, a current ratio of 1.57 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $681.83 million, a PE ratio of -138.83 and a beta of 0.97. The firm’s fifty day moving average is $18.46 and its 200 day moving average is $17.82.

Eton Pharmaceuticals (NASDAQ:ETON) last released its earnings results on Thursday, March 19th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative net margin of 5.75% and a negative return on equity of 2.60%. The firm had revenue of $21.28 million during the quarter, compared to the consensus estimate of $20.58 million. As a group, sell-side analysts predict that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.

Hedge Funds Weigh In On Eton Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. State of Alaska Department of Revenue purchased a new position in shares of Eton Pharmaceuticals in the third quarter worth $30,000. Ameritas Investment Partners Inc. purchased a new position in shares of Eton Pharmaceuticals during the 2nd quarter worth $37,000. Quarry LP bought a new stake in Eton Pharmaceuticals during the third quarter valued at about $37,000. Legal & General Group Plc bought a new position in shares of Eton Pharmaceuticals during the 2nd quarter valued at approximately $41,000. Finally, Caitong International Asset Management Co. Ltd bought a new position in shares of Eton Pharmaceuticals in the fourth quarter worth approximately $44,000. 27.86% of the stock is currently owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.